X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aventis Pharma with Fulford India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs FULFORD INDIA - Comparison Results

SANOFI INDIA    Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

FULFORD INDIA 
   Change

Fulford (India) Limited is an Indian affiliate of Schering-Plough Corporation, USA. The company has presence in oncology, virology and cardiovascular segments. In FY06 the topline of the company grew by 15.5% to Rs. 1519 m from Rs. 1279 m in FY05. PA... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SANOFI INDIA FULFORD INDIA SANOFI INDIA/
FULFORD INDIA
 
P/E (TTM) x 34.5 398.8 8.6% View Chart
P/BV x 6.9 6.2 111.4% View Chart
Dividend Yield % 1.3 0.1 1,539.4%  

Financials

 SANOFI INDIA   FULFORD INDIA
EQUITY SHARE DATA
    SANOFI INDIA
Dec-16
FULFORD INDIA
Mar-14
SANOFI INDIA/
FULFORD INDIA
5-Yr Chart
Click to enlarge
High Rs4,560942 484.1%   
Low Rs4,400450 977.8%   
Sales per share (Unadj.) Rs1,028.5691.4 148.8%  
Earnings per share (Unadj.) Rs129.011.5 1,125.2%  
Cash flow per share (Unadj.) Rs186.015.4 1,210.9%  
Dividends per share (Unadj.) Rs68.002.00 3,400.0%  
Dividend yield (eoy) %1.50.3 528.2%  
Book value per share (Unadj.) Rs753.6380.0 198.3%  
Shares outstanding (eoy) m23.033.90 590.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.41.0 432.7%   
Avg P/E ratio x34.760.7 57.2%  
P/CF ratio (eoy) x24.145.3 53.2%  
Price / Book Value ratio x5.91.8 324.6%  
Dividend payout %52.717.4 302.2%   
Avg Mkt Cap Rs m103,1742,714 3,801.0%   
No. of employees `0003.60.4 816.0%   
Total wages/salary Rs m3,592505 711.3%   
Avg. sales/employee Rs Th6,537.76,073.0 107.7%   
Avg. wages/employee Rs Th991.41,137.4 87.2%   
Avg. net profit/employee Rs Th819.8100.7 814.3%   
INCOME DATA
Net Sales Rs m23,6862,696 878.4%  
Other income Rs m708125 564.6%   
Total revenues Rs m24,3942,822 864.5%   
Gross profit Rs m5,281-46 -11,381.5%  
Depreciation Rs m1,31315 8,638.2%   
Interest Rs m1510 157.9%   
Profit before tax Rs m4,66154 8,583.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,69110 17,614.6%   
Profit after tax Rs m2,97045 6,644.3%  
Gross profit margin %22.3-1.7 -1,295.7%  
Effective tax rate %36.317.7 205.2%   
Net profit margin %12.51.7 756.4%  
BALANCE SHEET DATA
Current assets Rs m15,6731,738 901.6%   
Current liabilities Rs m6,678545 1,226.0%   
Net working cap to sales %38.044.3 85.8%  
Current ratio x2.33.2 73.5%  
Inventory Days Days7648 156.8%  
Debtors Days Days224 518.4%  
Net fixed assets Rs m8,09812 68,050.4%   
Share capital Rs m23039 590.5%   
"Free" reserves Rs m17,0881,443 1,184.2%   
Net worth Rs m17,3561,482 1,171.1%   
Long term debt Rs m00-   
Total assets Rs m25,4002,077 1,223.1%  
Interest coverage x311.76.7 4,641.8%   
Debt to equity ratio x00-  
Sales to assets ratio x0.91.3 71.8%   
Return on assets %11.82.6 450.3%  
Return on equity %17.13.0 567.3%  
Return on capital %26.94.3 625.8%  
Exports to sales %24.50-   
Imports to sales %28.024.5 114.4%   
Exports (fob) Rs m5,801NA-   
Imports (cif) Rs m6,627659 1,005.2%   
Fx inflow Rs m7,14517 41,540.7%   
Fx outflow Rs m6,846673 1,017.0%   
Net fx Rs m299-656 -45.6%   
CASH FLOW
From Operations Rs m3,22690 3,584.4%  
From Investments Rs m-1,555105 -1,486.6%  
From Financial Activity Rs m-1,818-14 12,893.6%  
Net Cashflow Rs m-147181 -81.4%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 60.4 75.0 80.5%  
Indian inst/Mut Fund % 14.4 3.8 378.9%  
FIIs % 14.6 0.1 14,600.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 21.2 49.5%  
Shareholders   15,184 4,783 317.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SANOFI INDIA With:   GLENMARK PHARMA  J.B.CHEMICALS  DR. REDDYS LAB  DIVIS LABORATORIES  UNICHEM LAB  

Compare SANOFI INDIA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Rising Oil Prices; RBI Minutes and Top Stocks in Action Today(Pre-Open)

Indian share markets surged on Wednesday, snapping a two-day losing streak led by gains Reliance Industries and bank stocks.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Jun 20, 2018 (Close)

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA - PANACEA BIOTECH COMPARISON

COMPARE SANOFI INDIA WITH

MARKET STATS